Safety and Efficacy of Dapagliflozin in Asian T2DM subjects with Inadequate glycemic control on Metformin/Saxagliptin

Trial Identifier: D1683C00008
Sponsor: AstraZeneca
NCTID:: NCT03608358
Start Date: February 2019
Primary Completion Date: August 2020
Study Completion Date: August 2020
Condition: Diabetes: Type 2

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Vietnamese translation
Thai translation
English version

Trial Locations

Country Location
Thailand Bangkok, Thailand, 10400
Thailand Bangkok, Thailand, 10330
Vietnam Ho Chi Minh, Vietnam, 700000
Vietnam Ho Chi Minh, Vietnam, 10000